

B8

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
22 August 2002 (22.08.2002)


PCT

(10) International Publication Number
WO 02/064808 A1

- (51) International Patent Classification⁷: C12P 13/08
- (21) International Application Number: PCT/KR02/00230
- (22) International Filing Date: 14 February 2002 (14.02.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
2001/6976 13 February 2001 (13.02.2001) KR
- (71) Applicant (*for all designated States except US*): CHEIL JEDANG CORPORATION [KR/KR]; 500, Namdaemun-ro 5ga, Jung-gu, 100-802 Seoul (KR).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): NOH, Kap-Soo
- (74) Agent: LEE, Young-Pil; The Cheonghwa Building, 1571-18, Seocho-dong, Seocho-gu, Seoul 137-874 (KR).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

[Continued on next page]

(54) Title: METHOD FOR L-TREONINE PRODUCTION



(57) Abstract: A method for producing L-threonine using a microorganism is provided. In the method, additional one or more copies of each of the phosphoenolpyruvate carboxylase (ppc) gene and the threonine operon are integrated into a particular site of the chromosomal DNA of a microorganism, while its inherent ppc gene and threonine operon remain. Accordingly, two or more ppc genes and threonine operons are included in the chromosomal DNA of the microorganism to thereby enhance the expression of the ppc gene encoding an enzyme to convert phosphoenolpyruvate to a threonine biosynthesis precursor, oxaloacetate, and the genes encoding enzymes involved in the synthetic pathway of threonine from oxaloacetate, including thrA (aspartokinaseI-homoserine dehydrogenase), thrB (homoserine kinase), and thrC (threonine synthase), thereby markedly increasing L-threonine productivity.

WO 02/064808 A1



GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(84) **Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

METHOD FOR L-THREONINE PRODUCTION

Technical Field

5 The present invention relates to the production of L-threonine involving microorganisms. More particularly, the present invention relates to a process for producing L-threonine with a high yield, in which additional one or more copies of the phosphoenolpyruvate carboxylase (*ppc*) gene and the threonine operon are inserted into a particular site of the chromosomal DNA of a microorganism, while
10 its inherent *ppc* gene and threonine operon remain, to increase the expression of the *ppc* gene encoding an enzyme to convert phosphoenol pyrvate to oxaloacetate, which is a threonine biosynthetic precursor, and the expression of genes encoding enzymes engaged in the synthetic pathway of threonine from oxaloacetate, such as aspartokinase-homoserine dehydrogenase (*thrA*), homoserine kinase (*thrB*),
15 and threonine synthase (*thrC*).

Background Art

20 L-threonine, a kind of essential amino acid, is widely used as an additive to animal fodder and food, and as fluids and synthetic materials for medical and pharmaceutical use. L-threonine is produced by fermentation using synthetic mutants derived from wild types of *Escherichia Coli*, *Corynebacterium*, *Serratia*, and *Providencia*. These variant strains are known to include amino acid analogs, pharmaceutical-resistant mutants, and synthetic pharmaceutical- resistant mutants rendered auxotrophic for diaminopimelic acid, methionine, lysine, or isoleucine
25 (Japanese Laid-open Patent Application No. hei 2-219582, *Appl., Microbiol. Biotechnol.*, 29, 550-553 (1988), and Korean Patent Publication No. 92-8365).

30 A common approach to increase the level of expression of a particular gene uses a plasmid that gives a greater copy number to a microorganism in order to increase the number of genes in the microorganism (*Sambrook et al., Molecular cloning, Second Edition, 1989, 1.3-1.5*). A target gene is integrated into a plasmid, and the host microorganism is transformed with the recombinant plasmid to cause an increase in the number of genes in the host microorganism according

to the copy number in the plasmid. A partial success in this type of approach to improve threonine productivity is reported in U.S. Patent No. 5, 538,873. However, most technologies using such recombinant plasmids overexpress a particular gene, which is undesirable for the host microorganism, and causes a 5 problem of plasmid instability so that the plasmid is lost during cultivation of the recombinant strain.

To address this problem, approaches to add antibiotics to culture media or to use an expression regulatory plasmid were suggested (*Sambrook et al. Molecular cloning, Second Edition, 1989, 1.5-1.6 & 1.9-1.11*). In using the 10 expression regulatory plasmid to yield a particular product, cell cultivation is performed under non-expression conditions in the growth stage to reduce a load to the host microorganism and temporary expression is induced after full growth of the microorganism. However, most expression regulatory plasmids target protein synthesis. Producing primary metabolites is closely associated with the growth of 15 microorganisms, so it is difficult to increase the yield of the primary metabolites unless target genes are expressed in the growth stage. The production of threonine, a primary metabolite, is such a case.

As an effort to compensate for this drawback, a particular threonine biosynthetic gene was incorporated into a chromosomal DNA to produce threonine 20 (U.S. Patent No. 5,939,307). However, this approach replaces a chromosomal gene by an inducible promoter-substituted gene, which is hardly expected to markedly increase the expression of the threonine operon gene.

Therefore, unlike the conventional substitution method, the present inventors have inserted an additional *ppc* gene and threonine operon into a 25 particular site (*lacZ* gene) of the chromosomal DNA while the original chromosomal gene of a host microorganism remains, and found that it provides dual effects as a result of the original chromosomal gene and the inserted *ppc* gene and threonine operon. Most current genetic engineering techniques applied to increase the yield of threonine are focused on the biosynthetic pathway, starting 30 with oxaloacetate. However, the present invention involves also *ppc*, which is an oxaloacetate inducer enzyme acting in the preceding step, as well as the threonine biosynthetic enzymes to purposely guide the flow of carbons from

phosphoenolpyruvate into the oxaloacetate synthetic pathway. The present invention also allows insertion of two or more copies of gene if necessary.

Disclosure of the Invention

5 To solve the above-described problems, it is an object of the present invention to provide a high-yield L-threonine production method which eliminates problems of plasmid instability and microbial growth inhibition arising with recombinant plasmid bearing strains and at the same time increases the expression of the phosphoenolpyruvate carboxylase (*ppc*) gene and the threonine operon.

10 The object of the present invention is achieved by a method of producing L-threonine using a microorganism, one or more copies of each of the phosphoenolpyruvate carboxylase gene and the threonine operon are additionally integrated into a particular site of the chromosomal DNA of the microorganism, 15 while its inherent phosphoenolpyruvate carboxylase gene and threonine operon remain.

According to the present invention, by incorporating two or more copies of the *ppc* gene and the threonine operon into the chromosomal DNA, the levels of expression of the *ppc* gene, which encodes an enzyme to convert 20 phosphoenolpyruvate to a threonine synthetic precursor, oxaloacetate, and the genes of enzymes engaged in the threonine synthesis from oxaloacetate, such as *thrA* (aspartokinase I-homoserine dehydrogenase), *thrB* (homoserine kinase), and *thrC*(threonine synthase).

According to the present invention, any microorganism capable of 25 producing L-threonine, including *Escherichia Coli*, *Corynebacterium*, *Serratia*, and *Providencia* can be used, but *Escherichia Coli* is more preferred.

It is preferable that the *ppc* gene and the threonine operon additionally inserted into the microorganism is derived from a microorganism (synthetic mutant) resistant to threonine analogs, lysine analogs, isoleucine analogs, and 30 methionine analogs.

According to the present invention, the *ppc* gene and the threonine operon may be additionally inserted into any site of the chromosomal DNA, except for the original threonine operon, but preferably into the *lacZ* gene site.

In the L-threonine production method according to the present invention, it
5 is preferable that a *ppc* gene obtained from the chromosome of a L-threonine producing *E.coli* strain, TF4076 (KFCC 10718), by polymerase chain reaction (PCR) and a threonine operon cloned from the same chromosome are inserted into the chromosome of the host *E.coli* strain TF4076.

10 **1. Threonine operon and phosphoenolpyruvate carboxylase gene**

The threonine operon and phosphoenolpyruvate carboxylase (*ppc*) gene used were cloned from the chromosome of TF4075 (Accession Number: KFCC10718, Korean Patent Application No. 90-22965). This strain is auxotrophic for methionine and resistant to threonine analogs (AHV: α-amino-β-hydroxyvaleric acid), lysine analogs (AEC: S-(2-aminoethyl)-L-cysteine), isoleucine analogs (α-aminobutyric acid) and methionine analogs (ethionine).

15 **2. Integration Vector**

pBRINT-TsGm, a plasmid vector for use in chromosomal integration, was
20 used (Sylvie Le Beatriz et al., 1998, *pBRINT-Ts: A plasmid family with a temperature-sensitive replicon, designed for chromosomal integration into the lacZ gene of Escherichia coli*, Gene., 223, pp. 213-219). This vector has temperature sensitivity; it integrates the cloned genes of a plasmide into a site of the *lacZ* gene of the chromosomal DNA when cultured at 37°C whereas the remaining plasmids in the plasma are lost when the cultivation temperature is raised to 44°C.

25 **3. Recombinant Vector**

The *ppc* gene derived from the chromosome of TF4076 by polymerase chain reaction (PCR) and the threonine operon derived from a vector cloned with
30 the threonine operon, pAT94 (Korean Patent Application No. 92-24732), were cloned into *BamH* I and *EcoR* I sites of pBRINT-TsGm to construct a recombinant plasmid vector pGmTN-PPC. Strain TF4076 was transformed with the

recombinant plasmid vector and then cultivated at 37°C to induce integration of the cloned *ppc* gene and threonine operon into the site of *lacZ* gene of the chromosomal DNA. Then, the cultivation was continued at 44°C to get rid of the remaining plasmids in the host strain.

5

4. Screening Method

Colonies that are resistant to gentamycin and sensitive to carbenicillin, and looks white, not blue, in a solid medium containing *X-gal* and *IPTG* were visually screened for recombinant strains. This screening method is based on the principle that integration of the *ppc* gene and the threonine operon into the *lacZ* gene of the chromosomal DNA inactivates the *lacZ* gene to lose its ability to decompose the chromophore *X-gal*.

These selected recombinant strains were compared with the host strain for threonine productivity. As a result, the host strain produced 20 g/L of threonine in 48 hours whereas pGmTN-PPC (Accession Number: KCCM-10236), one of the recombinant strains with the *ppc* gene and the threonine operon integrated into the chromosomal DNA, shows a highest threonine productivity at 27.0 g/L with a yield of about 35% (see Example 4). The pGmTN-PPC strain produces 102 g/L of threonine through fermentation in a 5-L fermentor with a higher yield of 35.4% than the host strain (see Example 5).

Brief Description of the Drawings

FIG. 1 depicts a process of cloning the phosphoenolpyruvate carboxylase (*ppc*) gene; and

25 FIG. 2 depicts the construction of a recombinant plasmid pGmTN-PPC cloned with the *ppc* gene and the threonine operon.

Best mode for carrying out the Invention

The present invention will be described in greater detail by means of the following examples. The following examples are for illustrative purposes and are not intended to limit the scope of the invention.

Example 1: Cloning of phosphoenolpyruvate carboxylase gene

The process of cloning the phosphoenolpyruvate carboxylase (*ppc*) gene is illustrated in FIG. 1. The *ppc* gene was obtained from a threonine producing strain, TF 4076. Chromosomal DNA was isolated, digested with restriction enzyme Sal I, and subjected to electrophoresis to selectively isolate 4-5 kb DNA fragments. The *ppc* gene was amplified by using the isolated DNA fragments as templates and using primer 1 (5'-aggaattctccgcagcattgacgtcac-3') and primer 2 (5'-aggaagctttagccgttacgcatacc-3'). The amplified product was digested with EcoR I and Hind III and subjected again to electrophoresis to finally isolate a 2.8 kb *ppc* gene fragment. A 7.6 kb pBRINT-TsGm, a kind of pBRINT-Ts vectors, from the National University of Mexico was used for cloning (Sylvie Le Beatriz et al., 1998, *pBRINT-Ts: A plasmid family with a temperature-sensitive replicon, designed for chromosomal integration into the lacZ gene of Escherichia coli*, Gene., 223, pp. 213-219). pBRINT-TsGm was double digested with the same restriction enzymes, EcoR I and Hind III, and ligated with the isolated *ppc* gene fragment by T4 DNA Ligase. *E.coli* strain DH5 α was transformed with the ligated DNA by electroporation and cultured on LB solid medium [yeast extract 5 g/L; bactotryptone 10 g/L; sodium chloride 10 g/L; bactoagar 1.7%; pH 7.0] containing antibiotics, 50 mg/L of carbenicillin and 5 mg/L of gentamycin. Next, single colonies were collected. Single colonies were cultivated on LB media containing the same antibiotics to isolate plasmids from the grown strains. The size of each plasmid was primarily identified and double digested with EcoR I and Hind III to isolate a 2.8 kb DNA fragment. The resulting DNA fragments were identified to thereby complete construction of a recombinant plasmid pGmPPC (10.7 kb) containing the *ppc* gene.

Example 2: Chromosomal DNA integration vector with threonine operon and *ppc* gene

Recombinant plasmid vector pAT94 (Korean Patent Application No. 92-24732) constructed by cloning with the chromosomal DNA of TF4076, was used for the threonine operon, and recombinant plasmid pGmPPC from Example 1 was used for the *ppc* gene. pBRINT-TsGm, a kind of pBRINT-Ts vectors, from

the National University of Mexico was used as a chromosomal DNA integration vector (Sylvie Le Beatriz et al., 1998, *pBRINT-Ts: A plasmid family with a temperature-sensitive replicon, designed for chromosomal integration into the lacZ gene of Escherichia coli.*, Gene., 223, pp. 213-219). A process of construction of
5 a recombinant plasmid is illustrated in FIG. 2. pAT94 was double digested with restriction enzymes Hind III and BamH I, and 6.4 kb threonine operon DNA fragments were isolated from the double digest by electrophoresis. pGmPPC was double digested with Hind III and EcoR I to isolate 2.8 kb *ppc* gene fragments.
10 pBRINT-TsGm plasmid vector was digested with EcoR I and BamH I, and completely digested DNA fragments were isolated by the same method. The resulting plasmid vector digest, isolated threonine operon DNA fragments, and *ppc* gene fragments were mixed and ligated by T4 DNA ligase. *E.coli* strain DH5 α was transformed with the ligated product by electroporation and cultured on LB solid medium [yeast extract 5 g/L; bactotryptone 10 g/L; sodium chloride 10 g/L;
15 bactoagar 1.7%; pH 7.0] containing antibiotics, 50 mg/L of carbenicillin and 5 mg/L of gentamycin. Next, single colonies were collected. Single colonies were cultivated on LB media containing the same antibiotics to isolate plasmids from the grown strains. The size of each plasmid was primarily identified and double digested with EcoR I and BamH I to isolate 9.2 kb and 7.9 kb DNA fragments.
20 The resulting DNA fragments were identified to thereby complete construction of a recombinant plasmid pGmTN-PPC (17.1 kb) containing the threonine operon and *ppc* gene.

Example 3: Screen of strain integrated with chromosomal
25 recombinant-plasmid

TF4076, a threonine producing strain, was transformed with the recombinant plasmid pGmTN-PPC isolated from *E.coli* strain DH5 α , cultured on LB solid medium [yeast extract 5 g/L; bactotryptone 10 g/L; sodium chloride 10 g/L; bactoagar 1.7%; pH 7.0] containing 5 mg/L of gentamycin, and cultivated for
30 60 hours at 30°C. Each single colony was inoculated into 0.5 mL of LB and incubated for 4 hours at 30°C. An aliquot of the culture was transferred into 10 mL of LB, incubated for 6 hours at 30°C and then overnight at 37°C. A 10⁻³-10⁻⁶

dilution of the culture was inoculated on LB solid medium containing 5 mg/L of gentamycin. At this time, 12 μ L of IPTG (0.1M) and 60 μ L of X-gal (2%) were also inoculated on the LB solid medium. After 24-hour incubation at 44°C, recombinant strains were screened for white colonies sensitive to carbenicillin, 5 which cannot grow on the LB solid medium containing 15 mg/L of carbenicillin. The screened recombinant stains confirmed the presence of the expected plasmids, in which the *ppc* gene and threonine operon were integrated into the *lacZ* gene site of the chromosomal DNA of each strain.

10 Example 4: Comparison of Threonine Productivity in Flask Cultivation for Recombinant Strains

Thirty single colonies of the recombinant strains with recombinant plasmids integrated into their chromosome were screened for threonine productivity comparisons using threonine titer media in Erlenmeyer flasks. The composition 15 of the threonine titer medium used in each case is shown in Table 1. Colonies were cultured on LB solid media overnight in a 32°C incubator. 20 mL of the titer medium was inoculated with a loopful of each culture and incubated at 32°C, 250 rpm for 48 hours. The results of the analysis are shown in Table 2. All thirty 20 colonies of recombinant strains show excellent productivity, including eight colonies that produced 26 g/L or greater threonine, compared to the host strain, TF 3076, which produced 20 g/L of threonine. The recombinant strain, which recorded the highest threonine productivity at 27 g/L with a 35% higher yield than the host strain, was named "pGmTN-PPC12". The strain pGmTN-PPC12 was deposited January 5, 2001 with the Korean Collection for Type Cultures (KCTC) 25 and was given Accession Number KCCM 10236.

Table 1. Composition of Threonine Titer Medium

Component	Amount per liter
Glucose	70 g
$(\text{NH}_4)_2\text{SO}_4$	28 g
KH_2PO_4	1.0 g
$\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$	0.5 g

FeSO ₄ ·7H ₂ O	5 mg
MnSO ₄ ·8H ₂ O	5 mg
Calcium carbonate	30 g
L-methionine	0.15 g
Yeast extract	2 g
PH 7.0	

Table 2. Results of Flask Titer Test for Recombinant Strains

L-threonine Concentration	20-22 g/L	22-24 g/L	24-26 g/L	26 g/L or greater
Colony Counts	7	6	9	8

5 Example 5: Comparison of Threonine Productivity using Fermentor

Threonine productivity in a fermentor was compared between recombinant strain pGmTN-PPC12 selected from its highest threonine titer from Example 4 and host strain TF4076. The initial medium composition used is shown in Table 3. LB media further containing per liter 10 g of glucose and 0.1 g of L-methionine were used for seed culture, and an initial volume of inoculation into a fermentor was determined at 3-5% by volume of a target initial culture. Glucose was added at a final concentration of 5% by weight each time, over 6 times in total, along with KH₂PO₄ at 1% by weight. Here, each addition of glucose was determined by deletion of glucose. The initial volume of the culture was 1.5L and the final volume of the culture was 3.0L. A total concentration of glucose added through fermentation was 250 g/L. During fermentations, the medium was stirred at 700-1000 rpm, temperature was controlled at 32°C, and pH was adjusted at 7.0 with 25-28% ammonia water. Air-flow velocity was adjusted at 0.1 vvm. The results are shown in Table 4. As shown in Table 4, the host strain TF4076 produces 75.3 g/L of threonine with a yield of 30.1% with respect to glucose consumption. In contrast, recombinant strain pGmTN-PPC12 produces 102 g/L threonine with a yield of 40.8%, which is 35.4% higher than the host strain TF4076. In addition, a similar fermentation pattern as the host strain was observed on the

recombinant strain, without reduction in sugar consumption during fermentation, which often appears on recombinant strains due to growth inhibition.

Table 3. Initial Medium Composition in 5-L Fermentor

Component	Amount per liter
Glucose	50 g
KH ₂ PO ₄	4 g
(NH ₄) ₂ SO ₄	6 g
Yeast extract	3 g
MgSO ₄ ·7H ₂ O	2 g
L-methionine	1 g
FeSO ₄ ·7H ₂ O	40 mg
MnSO ₄ ·8H ₂ O	10 mg
CaCl ₂ ·2H ₂ O	40 mg
CoCl ₂ ·6H ₂ O	4 mg
H ₃ BO ₃	5 mg
Na ₂ MoO ₄ ·2H ₂ O	2 mg
ZnSO ₄ ·7H ₂ O	2 mg
PH 7.0	

5

Table 4. Results of Fermentative Production of Threonine by Recombinant Strains

Strain	Threonine (g/L)	Fermentation Time (hr)	Yield (%)
TF4076	75.3	78	30.1
pGmTN-POC12	102	77	38.0

As described above, according to the present invention, two or more *ppc* genes and threonine operons are included in the chromosomal DNA to thereby enhance the expression of the *ppc* gene, which encodes an enzyme to convert phosphoenolpyruvate to a threonine biosynthesis precursor, oxaloacetate, and the genes encoding enzymes involved in the synthetic pathway of threonine from oxaloacetate, including *thrA* (aspartokinase-homoserine dehydrogenase), *thrB* (homoserine kinase), and *thrC* (threonine synthase). The present invention can remarkably improve productivity of L-threonine by 35% higher than the host strain.

**BUDAPEST TREATY ON THE INTERNATIONAL
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS
FOR THE PURPOSES OF PATENT PROCEDURE**

INTERNATIONAL FORM

To. CHEILJEDANG
500 5-GA NAMDAEMUN-RO
SEOUL, CHUNG-KU
KOREA, REPUBLIC OF

RECEIPT IN THE CASE OF AN ORIGINAL
issued pursuant to Rule 7.1 by the
INTERNATIONAL DEPOSITORY AUTHORITY
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR : pGmTN-PPC12	Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY: KCCM-10236
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depository Authority accepts the microorganism identified under I above, which was received by it on Dec. 29. 2000. (date of the original deposit) ¹	
IV. INTERNATIONAL DEPOSITORY AUTHORITY	
Name : Korean Culture Center of Microorganisms Address : 361-221, Yurim B/D Hongje-1-dong, Seodaemun-gu SEOUL 120-091 Republic of Korea	Signature(s) of person(s) having the power to represent the International Depository Authority of of authorized officer(s):  Date: Jan. 5. 2001.


¹ Where Rule 6.4(d) applies, such date is the date on which the status of international depository authority was acquired ; where a deposit made outside the Budapest Treaty after the acquisition of the status of international depository authority is converted into a deposit under the Budapest Treaty, such date is the date on which the microorganism was received by the international depository authority.

What is claimed is:

1. A method of producing L-threonine using a microorganism, one or more copies of each of the phosphoenolpyruvate carboxylase gene and the threonine operon are additionally integrated into a particular site of the chromosomal DNA of the microorganism, while its inherent phosphoenolpyruvate carboxylase gene and threonine operon remain.
2. The method of claim 1, wherein the microorganism is *Escherichia coli*.
- 10 3. The method of claim 1, wherein the phosphoenolpyruvate carboxylase gene and the threonine operon to be additionally integrated are derived from a microorganism resistant to threonine analogs, lysine analogs, isoleucine analogs, and methionine analogs.
- 15 4. The method of claim 1, wherein the phosphoenolpyruvate carboxylase gene and the threonine operon are additionally integrated into the lacZ gene site of the chromosomal DNA.
- 20 5. The method of claim 1, wherein the phosphoenolpyruvate carboxylase gene obtained from the chromosome of a threonine producing *E.coli* strain, TF4076, of Accession No. KFCC 10718 by polymerase chain reaction (PCR) and the threonine operon cloned from said *E.coli* strain are incorporated into the chromosome of the host strain *E.coli* TF4076.
- 25 6. The method of claim 1, wherein the microorganism is constructed with recombinant plasmid pGmTN-PPC of FIG. 2.
7. *Escherichia coli* strain pGmTN-PPC12 of Accession No. KCCM 10236 capable of L-threonine production.


1/2

FIG. 1



2/2

FIG. 2



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR02/00230

A. CLASSIFICATION OF SUBJECT MATTER		
IPC7 C12P 13/08		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC7 C12P, C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Korean Patents and applications for inventions since 1975		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CA, KIPASS, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JP 10-165180 A (HAYAKAWA Atsushi. et al) 23 JUNE 1998 see the whole document	1-7
A	US 5939307 A (Ming-Der Wang et al.) 17 AUGUST 1999 see the whole document	1-7
P, A	WO 2001-27258 A2 (Eitman, Mark et al) 19 APRIL 2001 see the whole document	1-7
<input type="checkbox"/> Further documents are listed in the continuation of Box C.		<input checked="" type="checkbox"/> See patent family annex.
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search 28 JUNE 2002 (28.06.2002)	Date of mailing of the international search report 28 JUNE 2002 (28.06.2002)	
Name and mailing address of the ISA/KR Korean Intellectual Property Office	Authorized officer	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR02/00230

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 10-165180 A	23-04-98	BR9706058 HU9702361 PL323545 SK163597 US6221636	12-08-98 24-04-01
US 5939307 A		NONE	
WO 2001-27258 A2	19-04-01	AU1206801 A	